1Johnson, S. Crisis resolution and home treatment teams: an evolving model. Adv Psychiatr Treat 2013; 19(2): 115–23.
2McCrone, P, Johnson, S, Nolan, F, Pilling, S, Sandor, A, Hoult, J, et al. Economic evaluation of a crisis resolution service: a randomised controlled trial. Epidemiol Psichiatr Soc 2009; 18(1): 54–8.
3Barker, V, Taylor, M, Kader, I, Stewart, K, Le Fevre, P. Impact of crisis resolution and home treatment services on user experience and admission to psychiatric hospital. Psychiatrist 2011; 35(3): 106–10.
4Hopkins, C, Niemiec, S. Mental health crisis at home: service user perspectives on what helps and what hinders. J Psychiatr Ment Health Nurs. 2007; 14(3): 310–8.
5Whiteford, HA, Degenhardt, L, Rehm, J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382(9904): 1575–86.
6Zipursky, RB, Menezes, NM, Streiner, DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 2014; 152: 408–414.
7Ascher-Svanum, H, Zhu, B, Faries, DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010; doi: 10.1186/1471-244X-10-2.
8Hor, K, Taylor, M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010; 24(4_supplement): 81–90.
9Guy, W. Clinical Global Impressions (CGI) Scale, Modified. In Task Force for the Handbook of Psychiatric Measures. Handbook of Psychiatric Measures (1st ed.) (ed A John). American Psychiatric Association, 2000.
10Leucht, S, Kane, JM, Etschel, E, Kissling, W, Hamann, J, Engel, RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006; 31(10): 2318–25.
11Chang, L, et al. Psychopathology, rehospitalization and quality of life among patients with schizophrenia under home care case management in Taiwan. Formosan Med Assoc 2013; 112: 208–15.
12Gomis, O, et al. Domiciliary intervention in psychosis: a systematic review. Actas Esp Psiquiatr 2017; 45(6): 290–302.
13Patel, MX, Bishara, D, Jayakumar, S, et al. Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. Eur Neuropsychopharmacol 2014; 24(4): 499–509.
14Langan, J, Shajahan, P. Antipsychotic polypharmacy: review of mechanisms, mortality and management. Psychiatrist 2010; 34(2): 58–62.
15Fleischhacker, WW, Uchida, H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol 2014; 17(7): 1083–93.
16Young, SL, Taylor, M, Lawrie, SM. ‘First do no harm.’ A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol 2015; 29: 353–62.
17Lacro, JP, Dunn, LB, Dolder, CR, Leckband, SG, Jeste, DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892–909.
18Hartz, SM, Pato, CN, Medeiros, H, Cavazos-Rehg, P, Sobell, JL, Genomic Psychiatry Cohort Consortium (GPCC), et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 2014; 71(3): 248–54.
19Menezes, PR, Johnson, S, Thornicroft, G, et al. Drug and alcohol problems among individuals with severe mental illness in south London. Br J Psychiatry 1996; 168(5): 612–9.
20Ajetunmobi, O, Taylor, M, Stockton, D, Wood, R. Early death in those previously hospitalised for mental healthcare in Scotland: a nationwide cohort study, 1986–2010. BMJ Open 2013; 3(7): e002768.